Support our sponsors:

NZX 50 Index	3326.74	2.10
S&P/ASX 200	4282.90	7.80
Dow Jones Industrials	12884.00	5.80

Twitter

Facebook

RSS

Daily ShareChat: Fisher & Paykel Healthcare

By Jenny Ruth

Friday 14th May 2010

Text too small?

The Fisher & Paykel Healthcare story is one of a short-term currency headwind and long-term strong sales growth, says First NZ Capital analyst Sarndra Urlich.

"We have assumed that Fisher & Paykel will deliver constant currency growth in the mid-teens for 2011. If the currency remains elevated, this will once again suppress the underlying story," Urlich says.

She has revised her long-term thinking about the company's obstructive sleep apnea (OSA) products and now believes it can keep up with competitor Resmed after 2011 with its ICON platform of continuous positive airway pressure (CPAP) devices to treat OSA.

Over the last couple of years, Fisher & Paykel had fallen behind with its flow generator sales, primarily due to holes in its product lines which have now been resolved, Urlich says.

"No one knows whether the ICON will be a 'killer app' or whether it is simply the next iteration of what will keep Fisher & Paykel up to speed with market growth rates (ie catch-up technology," she says.

The consistent narrative from key players is the US market is growing 15% a year by volume and 12% by revenue with global OSA revenues about US$2.2 billion (NZ$3.08 billion).

While Fisher & Paykel's growth matched the market during the years ended March 2008 and 2009, Urlich is expecting market share gains during 2010.

BROKER CALL: underperform.

Daily ShareChat articles report how the main experts in the market might view a certain share and we provide this commentary as a useful resource for investors. Content on this site does not in any way constitute a recommendation to buy, hold or sell any particular share. Investors should always seek professional advice before making any investment decisions.

Comments from our readers

No comments yet

Add your comment:

Your name:
Your email:	Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Printable version

Get quotes for Fisher & Paykel Healthcare Corporation L (FPH)

NZX Annoucements for FPH

9 Feb 2012	RELINT: FPH: Disclosure of Directors Relevant Interests
9 Feb 2012	GENERAL: FPH: CAREFUSION & FPH RENEW EXCLUSIVE DISTRIBUTION AGREEMENT
31 Jan 2012	SSH: FPH: SSH Mondrian Investment Partners Limited
11 Jan 2012	ALLOT: FPH: NOTIFICATION OF ISSUE OF SECURITIES